Invasive fungal infections (IFIs) cause an estimated 6.5 million cases and 3.8 million deaths annually. In 2022, the World Health Organisation identified Cryptococcus neoformans, Candidozyma auris, and Candida albicans as pathogens of critical concern. Current antifungal therapies are limited, with three of the four major drug classes targeting the fungal cell membrane and frequently causing toxicity due to the high genomic similarity between human and fungal cells. The emergence of multidrug-resistant (MDR) and pan-resistant strains further restricts treatment options. Cationic cyclic peptides (CCPs) offer a promising alternative, exploiting their positive charge to interact with negatively charged phospholipids in the fungal membrane and induce fungicidal activity. AR268, a novel CCP developed by the Robertson Group, has demonstrated potent efficacy against pathogenic yeasts. Ongoing research focuses on optimising AR268 and understanding how structural modifications influence potency and selectivity. These efforts underscore the potential of CCPs as a new class of antifungal therapeutics and provide insights into strategies for combating IFIs.